(Q38544516)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

review article

1 reference

title

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

author name string

James E Signorovitch

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Yan Song

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Rachael A Sorg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Junlong Li

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Ajay S Behl

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

Anupama Kalsekar

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

publication date

10 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

Journal of Comparative Effectiveness Research

19 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

page(s)

593-605

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

Global distribution and prevalence of hepatitis C virus genotypes

19 February 2020

cites work

1 reference

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

21 January 2018

1 reference

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

21 January 2018

1 reference

Treatment of hepatitis C: a systematic review

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial

21 January 2018

1 reference

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.

21 January 2018

1 reference

Daclatasvir + asunaprevir: first global approval

21 January 2018

1 reference

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study

21 January 2018

1 reference

Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

21 January 2018

1 reference

Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2.

21 January 2018

1 reference

Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.

21 January 2018

1 reference

Combination of direct and indirect evidence in mixed treatment comparisons

21 January 2018

1 reference

Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.

21 January 2018

1 reference

Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research

21 January 2018

1 reference

Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant d

21 January 2018

1 reference

Bayesian measures of model complexity and fit

21 January 2018

1 reference

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

21 January 2018

1 reference

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial

21 January 2018

1 reference

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.

21 January 2018

1 reference

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial

21 January 2018

1 reference

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

21 January 2018

1 reference

Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies

21 January 2018

1 reference

Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation

21 January 2018

1 reference

Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis

21 January 2018

1 reference

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

21 January 2018

1 reference

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

21 January 2018

1 reference

Extending methods for investigating the relationship between treatment effect and baseline risk from pairwise meta-analysis to network meta-analysis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/CER.15.33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26159375%20AND%20SRC:MED&resulttype=core&format=json

19 February 2020

1 reference